Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. [electronic resource]
Producer: 20140616Description: 4824-31 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Dose-Response Relationship, Drug
- Drug-Related Side Effects and Adverse Reactions -- classification
- Female
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasms -- blood
- Organophosphates -- administration & dosage
- Receptor, ErbB-2 -- metabolism
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.